Study Objective: This study checks how safe and effective a medicine called rocatinlimab is for people with moderate-to-severe atopic dermatitis (AD). Atopic dermatitis is a skin condition that makes your skin red, itchy, and sometimes swollen.
Who can join? To join, you must have completed a previous study with rocatinlimab within the last 28 days. If you were in the ROCKET-ORBIT study, your skin condition should have improved by 60% from the start of that study.
Who cannot join? You cannot take part if you stopped using rocatinlimab in the past study because of safety concerns or if there were other non-efficacy-related issues.
- **Study Duration:** Participants will continue the study after completing a previous rocatinlimab study.
- **Safety First:** The study focuses on understanding the safety and how well the medicine is tolerated.
- **Previous Participation Needed:** Must have been part of a previous rocatinlimab study recently.
How understandable was the trial content above?
Hard to understand
Easy to understand